Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK002 in active eosinophilic esophagitis
NL-OMON55008Phase 2Completed
- Sponsor
- Allakos Inc.
- Start
- Mar 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of lirentelimab in eosinophilic esophagitis (EoE) (3 arms), sponsored by Allakos Inc. Primary endpoints: Histologic remission at Week 24 and Change in Dysphagia Symptom Questionnaire score. Started Mar 2021; status: completed.
02
Drugs
lirentelimab
03
Conditions
eosinophilic esophagitis (EoE)
Beyond the preview
Go deeper on NL-OMON55008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55008.